Villoglandular papillary adenocarcinoma of the uterine cervix responding to neoadjuvant chemotherapy with docetaxel and cisplatin: a case report

被引:9
作者
Nagai, N [1 ]
Hirata, E
Kusuda, T
Mukai, K
Arihiro, K
Ohama, K
机构
[1] Hiroshima Univ, Grad Sch Biol Sci, Dept Obstet & Gynecol, Hiroshima 7348551, Japan
[2] Hiroshima Univ Hosp, Dept Pathol, Hiroshima, Japan
关键词
docetaxel and cisplatin; neoadjuvant chemotherapy; villoglandular papillary adenocarcinoma;
D O I
10.1111/j.1525-1438.2005.00186.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Villoglandular papillary adenocarcinoma (VGPA) of the uterine cervix is a rare neoplasm, and its treatment has rarely been reported. We report a patient with VGPA stage IIA responding to neoadjuvant chemotherapy with docetaxel (60 mg/m(2) as an intravenous infusion) and cisplatin (70 mg/m(2) as an intra-arterial infusion). At 3 weeks after completing one course of this regimen, the tumor size was reduced from 5.3 x 4.0 cm to 2.0 x 2.0 cm (81.1% reduction), revealed by computed tomography. Accordingly, the patient underwent radical hysterectomy, and there have been no signs of recurrence. Thus, the combination of docetaxel and cisplatin is suggested to be useful for neoadjuvant chemotherapy of cervical adenocarcinoma.
引用
收藏
页码:1187 / 1190
页数:4
相关论文
共 20 条
  • [1] Villoglandular papillary adenocarcinoma of the uterine cervix
    Collinet, P
    Prolongeau, JF
    Vaneecloo, S
    [J]. EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1999, 86 (01): : 101 - 103
  • [2] CERVICAL-CARCINOMA WITH GLANDULAR DIFFERENTIATION - HISTOLOGICAL-EVALUATION PREDICTS DISEASE RECURRENCE IN CLINICAL STAGE-I OR STAGE-II PATIENTS
    COSTA, MJ
    MCILNAY, KR
    TRELFORD, J
    [J]. HUMAN PATHOLOGY, 1995, 26 (08) : 829 - 837
  • [3] Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: A Gynecologic Oncology Group Study
    Curtin, JP
    Blessing, JA
    Webster, KD
    Rose, PG
    Mayer, AR
    Fowler, WC
    Malfetano, JH
    Alvarez, RD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) : 1275 - 1278
  • [4] FU YS, 1982, CANCER, V49, P2560, DOI 10.1002/1097-0142(19820615)49:12<2560::AID-CNCR2820491225>3.0.CO
  • [5] 2-G
  • [6] PAPILLARY VILLOGLANDULAR CARCINOMA OF THE CERVIX
    HOPSON, L
    JONES, MA
    BOYCE, CR
    TARRAZA, HM
    [J]. GYNECOLOGIC ONCOLOGY, 1990, 39 (02) : 221 - 224
  • [7] *JAP SOC OBST GYN, 1997, GEN RUL CLIN PATH MA
  • [8] WELL-DIFFERENTIATED VILLOGLANDULAR ADENOCARCINOMA OF THE UTERINE CERVIX - A CLINICOPATHOLOGICAL STUDY OF 24 CASES
    JONES, MW
    SILVERBERG, SG
    KURMAN, RJ
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1993, 12 (01) : 1 - 7
  • [9] Adenocarcinoma of the uterine cervix with predominantly villogladular papillary growth pattern
    Kaku, T
    Kamura, T
    Shigematsu, T
    Sakai, K
    Nakanami, N
    Uehira, K
    Amada, S
    Kobayashi, H
    Saito, T
    Nakano, H
    [J]. GYNECOLOGIC ONCOLOGY, 1997, 64 (01) : 147 - 152
  • [10] COMBINATION CHEMOTHERAPY FOR METASTATIC OR RECURRENT ADENOCARCINOMA OF THE CERVIX
    KAVANAGH, JJ
    GERSHENSON, D
    COPELAND, L
    ROBERTS, WS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (10) : 1621 - 1623